Clinical trials
Prostate Cancer (Adenocarcinoma) clinical trials
Below are recruiting prostate cancer (adenocarcinoma) clinical trials, each written for real people, not researchers. We’re tracking 541 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06798558RecruitingPhase 2
Lu-PSMA before prostate surgery for high-risk cancer
This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05915442RecruitingPhase 2
Adenosine blocker plus immunotherapy for limited prostate spread
This Phase 2 study tests a medicine that affects “adenosine” signaling along with an immune checkpoint inhibitor (immunotherapy) in men with hormone-sensitive prostate cancer that has spread in only a small, limited way. It aims to stop or slow that limited spread by helping the immune system work better.
New York, New YorkAges 18–99 - NCT07198633RecruitingPhase 1/Phase 2
Study of new drugs for advanced prostate cancer
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06335914Recruiting
Dual PET scans for advanced prostate cancer
This study tests whether two kinds of PET scans, one targeting PSMA and one targeting sugar uptake (FDG), can help doctors better understand advanced prostate cancer. If you have prostate cancer that has spread (metastatic) and still responds to hormone therapy, the scans may help guide your treatment.
Toronto, OntarioAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT05011383RecruitingPhase 2
High dose testosterone for prostate cancer with ATM, CDK12, or CHEK2 changes
This trial is testing whether high doses of testosterone can help treat advanced prostate cancer in men who have a specific genetic change (ATM, CDK12, or CHEK2). It is for patients whose cancer has stopped responding to current hormone therapies.
Aurora, ColoradoAges 18 years+ - NCT03237026Recruiting
Urine tests to predict outcomes in prostate cancer treatment
This study looks for urine markers (proteins and metabolites) that may help predict how prostate cancer patients respond to treatment and what their outcomes are. You may be asked to give a urine sample and allow use of your medical and treatment details for analysis (results are not shared with you).
TaipeiAges 30–100 - NCT03408964Recruiting
Blood tests to predict treatment response in prostate cancer
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
BellinzonaAges 18 years+ - NCT05000827Recruiting
PSMA PET scan to guide lymph node surgery in prostatectomy
This study tests whether a special prostate scan called PSMA PET/CT can help doctors decide which pelvic lymph nodes to remove during prostate surgery. It may improve who needs lymph node surgery by using scan results to guide the operation.
Nijmegen, GelderlandAges 18 years+ - NCT06085729RecruitingPhase 1/Phase 2
Study of ADI-PEG20 with chemo for aggressive prostate cancer
This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT06267729RecruitingPhase 1/Phase 2
A new cell therapy for advanced prostate cancer
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
Duarte, CaliforniaAges 18–130 - NCT06640166RecruitingPhase 2
Encorafenib + Cetuximab with FOLFIRI after progression
This trial tests adding a new chemotherapy regimen (FOLFIRI) to the combination of Encorafenib and Cetuximab for people with a specific type of advanced colorectal cancer that has started growing again after initial treatment with Encorafenib and Cetuximab. The goal is to see if the new combination can help control the cancer longer.
MilanAges 18 years+ - NCT06774781Recruiting
Using MRI to find prostate tumors
This study uses advanced MRI scans to better identify prostate cancer lesions before biopsy or surgery. It may help men who already have suspicious MRI findings and are scheduled for a prostate biopsy or removal.
BolognaAges 18 years+ - NCT07181161RecruitingPhase 1/Phase 2
Testing a new drug for metastatic prostate cancer
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
Fayetteville, ArkansasAges 18–130 - NCT07529717RecruitingPhase 1/Phase 2
Early-stage study of AZD8359 for advanced prostate cancer
This study tests a new experimental drug (AZD8359) designed to target prostate cancer cells in men whose cancer has progressed despite previous treatments. The drug works by directing immune cells to attack cancer cells.
Orlando, FloridaAges 18–100 - NCT05306600Recruiting
Study genes in breast and prostate cancers in Brazil
This study looks at tumor tissue and blood to map genetic features of breast and prostate cancers in Brazil. It helps understand cancer patterns in the public health system and may guide future testing and treatments.
Manaus, AmazonasAges 18 years+ - NCT07455903RecruitingPhase 2
Hormone therapy before surgery for high-risk prostate cancer
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
Miami, FloridaAges 18 years+ - NCT05942001RecruitingPhase 1
Testing an investigational drug for advanced prostate cancer
This Phase 1 trial tests HRS-5041 in people with metastatic castration-resistant prostate cancer (prostate cancer that keeps growing despite lower testosterone). It aims to see if the drug can be given safely and whether it may help control the cancer after prior standard treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05563558RecruitingPhase 2
Testing pembrolizumab plus chemotherapy for aggressive metastatic prostate cancer
This Phase 2 trial tests pembrolizumab together with carboplatin and cabazitaxel in men with aggressive, metastatic prostate cancer that has become resistant to hormone therapy. It may help shrink tumors and improve outcomes for people with hard-to-treat forms of prostate cancer.
MadridAges 18 years+ - NCT06408298RecruitingEarly Phase 1
Hydroxychloroquine before prostate cancer surgery
This trial tests whether a drug called hydroxychloroquine (HCQ) can help before prostate cancer surgery. It is for people with localized prostate cancer who are planning to have their prostate removed.
Lebanon, New HampshireAges 18 years+ - NCT07693075RecruitingPhase 2
Radiotherapy for high-risk prostate cancer with boost to tumor
This trial tests a special type of radiation therapy that gives a higher dose to the tumor while treating the whole prostate. It is for men with high-risk or very high-risk prostate cancer that has not spread to distant organs.
CairoAges 18 years+ - NCT04035642Recruiting
Single high-dose MRI-guided radiation for intermediate prostate cancer
This trial tests whether a single, image-guided radiation treatment can treat intermediate-risk prostate cancer while better protecting the urethra (the urine tube). It may help patients get effective cancer control with potentially fewer urinary side effects, depending on the results.
LisbonAges 18 years+ - NCT05304858Recruiting
Study of prostate cancer spread using biopsy and lab tests
This trial studies the “microenvironment” around prostate cancer metastases, using specimens taken during biopsy and other scans. It may help researchers understand what drives prostate cancer spread and improve future treatment choices.
New York, New YorkAges 18 years+ - NCT05983783RecruitingPhase 3
Testing two drug combinations for advanced prostate cancer
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
Nanjing, JiangsuAges 40–80
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (adenocarcinoma)?
- Yes. Clin2 currently lists 541 recruiting prostate cancer (adenocarcinoma) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (adenocarcinoma) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (adenocarcinoma) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.